NCT00487656

Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation

Name: Clinical Trial NCT00487656
Creator: Artisan Pharma, Inc.
Keywords: Sepsis,Disseminated Intravascular Coagulation, ART-123, Phase 2, drug, clinical trial, Canada,Malaysia,Thailand,United States of America

A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects With Sepsis and Disseminated Intravascular Coagulation

Artisan Pharma, Inc.·Phase 2·ClinicalTrials.gov·drugCompleted

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Sepsis,Disseminated Intravascular Coagulation
Drug/Device/Intervention: ART-123
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Artisan Pharma, Inc.
Location: Birmingham,Phoenix,Tuscon,Bakersfield,Colton,Loma Linda,Long Beach,Los Angeles,Rancho Mirage,San Diego,San Francisco,Stanford,Hartford,Bay Pines,Celebration,Jacksonville,Miami,Orlando,Atlanta,Augusta,, Canada,Malaysia,Thailand,United States of America

Timeline & enrollment

Phase: Phase 2
Start date: Jul 01, 2007
End date: Aug 01, 2010
Enrollment: 750 participants

Primary outcome

28-Day All-cause mortality

Summary

The purpose of this study is to see if ART-123 (recombinant human soluble thrombomodulin) decreases the number of people who die as a result of Disseminated Intravascular Coagulation (DIC) complication of sepsis.

ICD-10 classifications

Disseminated intravascular coagulation of fetus and newbornDisseminated intravascular coagulation [defibrination syndrome]Sepsis, unspecifiedOther specified sepsisOther sepsis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT00487656
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT00487656 through Pure Global AI's free database. This Phase 2 trial is sponsored by Artisan Pharma, Inc. and is currently Completed. The study focuses on Sepsis,Disseminated Intravascular Coagulation. Target enrollment is 750 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.